What steps should I take during a patient appointment to assess and safely refill Adderall (amphetamine) for ADHD?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adderall Refill Appointment: Essential Assessment and Management Protocol

For an Adderall refill appointment, you must systematically assess treatment response, monitor for side effects and cardiovascular changes, screen for substance misuse/diversion risk, and verify ongoing ADHD symptom control before authorizing the refill.

Pre-Refill Assessment Checklist

1. Treatment Response Evaluation

  • Assess target ADHD symptoms using standardized rating scales 1:

    • For adults: obtain self-ratings using validated instruments (Adult ADHD Self-Report Scale or Conners Adult ADHD Rating Scale) 1
    • Document functional improvement in at least two settings (work/school AND home/social) 1
    • Ask specifically: "Are you still experiencing difficulty with attention, impulsivity, or hyperactivity that interferes with your daily functioning?"
  • Evaluate medication adherence 1:

    • Review prescription fill history via prescription drug monitoring program (PDMP)
    • Ask: "How many pills do you have left?" and calculate if usage matches prescribed dosing
    • Inquire about missed doses and reasons

2. Side Effects Monitoring (Required at Every Visit)

Systematically ask about these specific side effects 1:

  • Insomnia or sleep disturbances
  • Decreased appetite/anorexia
  • Headaches
  • Stomach aches
  • Social withdrawal
  • Tics or involuntary movements
  • Jitteriness/nervousness
  • Irritability when medication wears off

Objective measurements required 1:

  • Weight: Document at every visit to objectively assess appetite suppression 1
  • Blood pressure and pulse: Check quarterly in adults 1; monitor for increases >5-15% above baseline 2
  • Height (if child/adolescent): Monitor for growth attenuation, which averages 1-2 cm reduction from predicted adult height 2

3. Cardiovascular Safety Assessment

At baseline and ongoing 1:

  • Blood pressure and pulse monitoring (quarterly minimum for adults)
  • Ask about: chest pain, palpitations, syncope, exercise intolerance
  • Review for new cardiovascular symptoms since last visit

Do NOT routinely order ECGs unless cardiac risk factors are present 3.

4. Substance Misuse and Diversion Screening

Critical questions to ask 4, 5:

  • "Has anyone asked you for your medication or have you shared/sold any pills?"
  • "Are you taking more than prescribed or taking it differently than directed?"
  • "Are you using alcohol or other substances?" (obtain detailed drug/alcohol history) 1
  • Consider urine drug screen if concerned about concurrent substance use 1

Review PDMP for:

  • Early refills
  • Multiple prescribers
  • Concurrent controlled substances from other providers

Implement controlled substance agreement for ongoing monitoring 4.

5. Dose Optimization Assessment

If symptoms are not adequately controlled 1:

  • Current dose may be suboptimal—stimulants are often underdosed in practice 6
  • For immediate-release amphetamine salts: increase by 2.5-5 mg increments weekly 1
  • Maximum FDA-approved dose: 40 mg/day for amphetamines 1, 7
  • However, clinical practice may occasionally exceed these limits when titrated carefully based on response and tolerability 6, 8

If previously effective dose is losing efficacy 9:

  • Consider tolerance development (occurs in 2.7-24.7% of patients)
  • Options: switch to different stimulant formulation, implement drug holidays, or reassess diagnosis
  • Ensure compliance first before assuming tolerance

6. Comorbidity Assessment

Screen for new or worsening psychiatric conditions 1:

  • Depression or mood instability
  • Anxiety symptoms (note: stimulants can be used with comorbid anxiety) 1, 10
  • Psychotic symptoms (absolute contraindication—discontinue immediately) 1
  • Substance use disorders

7. Documentation Requirements

Before authorizing refill, document 1:

  • Current ADHD symptom severity and functional impairment
  • Medication adherence
  • Side effects present/absent
  • Vital signs (BP, pulse, weight)
  • PDMP review findings
  • Justification for current dose
  • Plan for next follow-up

Refill Decision Algorithm

AUTHORIZE REFILL if:

  • ADHD symptoms remain present and impairing
  • Current dose provides benefit without intolerable side effects
  • No evidence of misuse/diversion
  • Vital signs acceptable (BP/pulse increases <15% from baseline)
  • PDMP shows appropriate usage pattern

DO NOT REFILL if:

  • Evidence of diversion or misuse
  • Development of psychotic symptoms 1
  • Uncontrolled hypertension or new cardiovascular symptoms 1
  • Patient lost to follow-up >3 months without contact 1
  • Pregnancy (relative contraindication—requires risk-benefit discussion)

MODIFY TREATMENT if:

  • Inadequate symptom control: increase dose in 2.5-5 mg increments 1
  • Intolerable side effects: reduce dose or switch formulation 1
  • Tolerance suspected: consider drug holiday or switch stimulant type 9
  • New comorbid substance use: consider switching to non-stimulant (atomoxetine) 11

Follow-Up Schedule

  • During dose titration: Weekly contact (can be by phone) 1
  • After stabilization: Monthly until symptoms stabilized 1
  • Maintenance phase: Every 1-3 months depending on stability, comorbidities, and adherence concerns 1

Critical Pitfalls to Avoid

  1. Failing to check PDMP before every refill—this is essential for detecting diversion 4
  2. Not weighing the patient—weight loss is an objective marker of appetite suppression 1
  3. Assuming tolerance without verifying adherence first 9
  4. Stopping medication if tics emerge—controlled trials show stimulants don't worsen tics in most patients 1
  5. Underdosing—many patients require doses at the higher end of the FDA range for optimal response 6, 8
  6. Refilling without documented functional impairment—ADHD must cause moderate-to-severe impairment in ≥2 settings to justify continued treatment 1

References

Guideline

practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.

Journal of the American Academy of Child and Adolescent Psychiatry, 2002

Research

Attention-Deficit/Hyperactivity Disorder in Adults.

American family physician, 2024

Related Questions

What is the appropriate dosage of mixed amphetamine salts extended‑release (Adderall XR) when switching a patient from 60 mg lisdexamfetamine (Vyvanse)?
What is the recommended starting dose and titration plan for Adderall (mixed amphetamine salts) for an adult patient already taking sertraline 30 mg daily?
In a 13‑year‑old with attention‑deficit/hyperactivity disorder, should treatment begin with a stimulant or a non‑stimulant, and what are the recommended dosing and monitoring considerations?
If I stopped Adderall (amphetamine/dextroamphetamine) for five years, can I restart it at the same 20 mg dose?
In a 12‑year‑old with ADHD currently taking fluoxetine (Prozac), what stimulant medication and dosing regimen is appropriate?
When is antiplatelet therapy appropriate in thrombocytopenic patients, and what platelet count thresholds should be used for low‑dose aspirin, clopidogrel, and ticagrelor?
How should a 45-year-old with newly diagnosed rheumatic heart disease, severe mitral stenosis, moderate mitral regurgitation, moderate aortic regurgitation, and a marked blood‑pressure discrepancy (right arm 120/50 mm Hg, left arm ~20 mm Hg by palpation) be managed?
In a patient taking desvenlafaxine, buspirone, temazepam, divalproex, duloxetine, levothyroxine, and oxbutynin, which of these medications are likely causing hyponatremia and what is the recommended management?
In an adult with treatment‑resistant major depressive disorder and a history of a suicide attempt, who is currently on fluoxetine 80 mg daily, lithium 600 mg daily, and buspirone 5 mg three times daily, is it appropriate to increase lithium to 900 mg and check a serum lithium level five days after the dose change?
How should silodosin and mirabegron be used together to treat a patient with benign prostatic hyperplasia‑related voiding difficulty and overactive bladder, including appropriate dosing, contraindications, and monitoring?
When should a patient with ADHD be referred to a psychiatrist and what other groups or services can assist?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.